Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma
- 58 Downloads
For patients with differentiated thyroid carcinoma (DTC), distant metastases are commonly identified in the lungs and bones. However, they are relatively rare in other distant organs, such as the liver, kidneys, or brain. The aim of the current study was to describe the clinical outcomes and evaluate the prognostic factors of patients with no less than three different distant organ system metastases from DTC.
This study retrospectively identified 717 patients diagnosed with DTC with distant metastases between January 2005 and December 2017. Patient response to radioactive iodine (RAI) therapy was monitored by changes in serum thyroglobulin levels and imaging changes. Five-year and 10-year overall survival (OS) rates were calculated by the Kaplan–Meier methods and Cox proportional hazards.
Among the 717 participants, 37 (5.16%) patients had no less than three different distant organ system metastases from DTC. Five-year and 10-year OS were 45.9% and 37.8% in patients with three or more distant organ system metastases while 74.5% and 64.9% in individuals with one or two distant organ system metastases, respectively. RAI avidity and RAIR-DTC were main independent prognostic factors influencing the clinical outcomes for both groups of patients. The presence of 3 or more different distant organ system metastases was the only independent prognostic factors for 10-year OS by multivariate analysis.
Patients with no less than three distant organ system metastases from DTC had poor prognosis. RAI avidity and RAIR-DTC were main factors influencing overall survival for patients with distant metastases from DTC in both groups.
KeywordsDifferentiated thyroid carcinoma Distant metastases Multiple distant organ system metastases Radioactive iodine therapy Overall survival
The authors thank the American Journal Experts for their help with the edition for proper English language, grammar, punctuation, spelling, and overall style by one or more of the highly qualified native English-speaking editors for this paper. This study was supported by the National Natural Science Foundation of China (Grant number 81671712) and the Shanghai Key Discipline of Medical Imaging (Grant number 2017ZZ02005).
X.Y.Z. and Z.L.Q. designed the study. X.Y.C. and J.W.S. conducted the statistical analysis. Y.W. collected the clinical data. X.Y.Z. wrote the whole paper. J.H.Z. and Q.Y.L. supervised and edited the paper. All authors read and approved the final paper.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 7.A.B. Sheikh, A. Akhtar, U. Tariq, A.A.E. Sheikh, F.S. Siddiqui, M.M. Bukhari, Skull metastasis extending to the superior sagittal sinus: an unfamiliar presentation of papillary thyroid carcinoma. Cureus 10(6), e2738 (2018). https://doi.org/10.7759/cureus.2738 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.L.Y. Wang, F.L. Palmer, I.J. Nixon, D. Thomas, S.G. Patel, A.R. Shaha, J.P. Shah, R.M. Tuttle, I. Ganly, Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24(11), 1594–1599 (2014). https://doi.org/10.1089/thy.2014.0173 CrossRefPubMedGoogle Scholar
- 12.B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.H.G. Vuong, U.N.P. Duong, T.Q. Pham, H.M. Tran, N. Oishi, K. Mochizuki, T. Nakazawa, L. Hassell, R. Katoh, T. Kondo, Clinicopathological risk factors for distant metastasis in differentiated thyroid carcinoma: a meta-analysis. World J. Surg. 42(4), 1005–1017 (2018). https://doi.org/10.1007/s00268-017-4206-1 CrossRefPubMedGoogle Scholar
- 16.D. Casara, D. Rubello, G. Saladini, G. Masarotto, A. Favero, M.E. Girelli, B. Busnardo, Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J. Nucl. Med. 34(10), 1626–1631 (1993)PubMedGoogle Scholar
- 17.B.H. Lang, K.P. Wong, C.Y. Cheung, K.Y. Wan, C.Y. Lo, Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann. Surg. Oncol. 20(4), 1329–1335 (2013). https://doi.org/10.1245/s10434-012-2711-x CrossRefPubMedGoogle Scholar
- 18.Y. Saito, K. Sugino, H. Takami, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, H. Kawakubo, K. Ito, Y. Kitagawa. Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J. Surg. (2018). https://doi.org/10.1007/s00268-018-4676-9 CrossRefGoogle Scholar
- 25.H. Kim, H.I. Kim, S.W. Kim, J. Jung, M.J. Jeon, W.G. Kim, T.Y. Kim, H.K. Kim, H.C. Kang, J.M. Han, Y.Y. Cho, T.H. Kim, J.H. Chung, Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea. Endocrinol. Metab. 33(2), 287–295 (2018). https://doi.org/10.3803/EnM.2018.33.2.287 CrossRefGoogle Scholar
- 28.G. Mazziotti, A.M. Formenti, M.B. Panarotto, E. Arvat, A. Chiti, A. Cuocolo, M.E. Dottorini, C. Durante, L. Agate, S. Filetti, F. Felicetti, A. Filice, L. Pace, T. Pellegrino, M. Rodari, M. Salvatori, C. Tranfaglia, A. Versari, D. Viola, S. Frara, A. Berruti, A. Giustina, R. Giubbini, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59(1), 90–101 (2018). https://doi.org/10.1007/s12020-017-1455-6 CrossRefPubMedGoogle Scholar
- 30.C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006). https://doi.org/10.1210/jc.2005-2838 CrossRefPubMedGoogle Scholar
- 31.P.M. Manohar, L.J. Beesley, E.L. Bellile, F.P. Worden, A.M. Avram, Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin. Nucl. Med. 43(9), 641–647 (2018). https://doi.org/10.1097/RLU.0000000000002193 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.M. Schlumberger, C. Challeton, F. De Vathaire, J.P. Travagli, P. Gardet, J.D. Lumbroso, C. Francese, F. Fontaine, M. Ricard, C. Parmentier, Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37(4), 598–605 (1996)PubMedGoogle Scholar